利德曼（300289）公告，公司正在筹划以支付现金方式收购北京先声祥瑞生物制品股份有限公司部分股 东持有的目标公司合计不超过70%的股份。交易资金来源拟运用自有资金并结合银行并购贷款等方式筹 集资金。交易前，公司未持有目标公司的股份；交易完成后，公司将取得目标公司控制权，目标公司将 成为公司的控股子公司。根据初步测算，本次交易预计构成《上市公司重大资产重组管理办法》规定的 重大资产重组。本次交易不涉及上市公司发行股份，不构成关联交易，也不会导致公司控制权变更。 ...

证券代码：300289 证券简称：利德曼 公告编号：2025-029 北京利德曼生化股份有限公司 关于筹划重大资产重组暨签署投资框架协议的提示性 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 审批程序，存在未能通过有关决策、审批程序的风险。本次交易相关 事项尚存在重大不确定性，敬请广大投资者注意投资风险。 5、根据《上市公司股票停复牌规则》《深圳证券交易所上市公司 自律监管指引第 6 号——停复牌》等相关规定，本次交易筹划事项公 司股票不停牌，公司将根据相关事项的进展情况，分阶段及时履行信 息披露义务，敬请广大投资者注意投资风险。 一、本次交易事项概述 2025 年 7 月 30 日，公司与目标公司、目标公司股东上海百家汇 投资管理有限公司、海南先声百家汇科技发展有限公司、南京百佳瑞 企业管理咨询合伙企业（有限合伙）签署了《框架协议》，公司拟以现 金方式收购目标公司合计不超过 70%的股份。本次交易前，公司未持 有目标公司的股份；本次交易完成后，公司将成为目标公司控股股东， 目标公司将成为公司的控股子公司。 根据《上市公司重大资产重组管理办 ...

北京利德曼生化股份有限公司(以下简称"公司")于 2025 年 3 月 4 日召开第六届董事会第二次会议和第六届监事会第二次会议，审议通过 了《关于使用闲置自有资金进行委托理财的议案》，同意公司及子公司 使用额度不超过人民币70,000万元的暂时闲置自有资金进行委托理财， 用于购买银行、证券公司、信托公司、基金管理公司等金融机构发行的 安全性高、流动性好、中低风险的现金管理类产品或理财产品等，上述 额度自公司董事会审议通过之日起 12 个月内可循环滚动使用。内容详 见公司在巨潮资讯网（www.cninfo.com.cn）披露的《关于使用闲置自 有资金进行委托理财的公告》（公告编号：2025-007）、《关于使用闲置 自有资金进行委托理财的进展公告》（公告编号：2025-027）。 一、公司使用闲置自有资金进行委托理财进展情况 1、公司近期购买的银行理财产品到期赎回及取得收益情况： | 交易方 | 产品 | 类型 | 金额 （万 | 起息 | | 到期日 | | 预计年化收益率 | 赎回本金 | 实际收 益（万 | | --- | --- | --- | --- | --- | --- | --- | --- ...

证券代码：300289 证券简称：利德曼 公告编号：2025-027 北京利德曼生化股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 | 产品 类型 | 金额 （万 | 起息 | | 到期日 | | 预计年化收益率 | 赎回本金 | 实际收 益（万 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 元） | 日 | | | | | （万元） | 元） | | 保本 浮动 | 8,000 | 2025 年 1 | 月 | 2025 7 月 | 年 7 | 1.3%-2.51% | 8,000 | 100.12 | | 收益 | | | | | | | | | | 公司 型 | | 6 日 | | 日 | | | | | | 交易方 华夏银行 股份有限 | | | | | | | | | | 名称 结 构 性 存 款 | | | | | | | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2025 年 3 月 4 日召开第 ...

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Group 1 - The core business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and Innovative Enterprise" [1] - As of the first quarter of 2025, Lidman reported a revenue of 78.91 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25 million yuan, a year-on-year increase of 53.73% [1] Group 2 - The latest closing price of Lidman was 5.22 yuan, with a market capitalization of 2.84 billion yuan and a price-to-book ratio of 1.71, marking a new low in 79 days [1] - The company is held by three institutions, with a total holding of 263.08 million shares valued at 1.24 billion yuan [1] - The industry average price-to-earnings ratio (PE) is 50.99, while Lidman's PE (TTM) is -38.56, indicating a significant divergence from industry norms [2]

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Lidman Biochemical Co., Ltd, including its stock price, market capitalization, and financial results for Q1 2025 [1] - On June 3, Lidman closed at 5.05 yuan, up 1.41%, with a latest price-to-book ratio of 1.65, marking a new low in 49 days and a total market value of 2.747 billion yuan [1] - The company experienced a net outflow of main funds amounting to 8.4668 million yuan on June 3, with a total outflow of 25.8327 million yuan over the past five days [1] Group 2 - Lidman specializes in the research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with key products including biochemical diagnostic reagents and automated chemiluminescence immunoassay analyzers [1] - The company has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and New Small and Medium-sized Enterprises," and has been recognized as a leading enterprise in the Beijing biopharmaceutical industry [1] - The latest financial report for Q1 2025 shows that the company achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25172554 million yuan, a year-on-year increase of 53.73%, with a gross sales margin of 53.56% [1] Group 3 - The price-to-earnings (P/E) ratio for Lidman is reported at -37.30 (TTM) and -36.58 (static), with a price-to-book ratio of 1.65 and a total market capitalization of 2.747 billion yuan [2] - The industry average P/E ratio is 50.80 (TTM) and 49.07 (static), with an average price-to-book ratio of 4.67 and a total market capitalization of 108.36 billion yuan [2] - The industry median P/E ratio stands at 36.71 (TTM) and 36.84 (static), with a median price-to-book ratio of 2.48 and a total market capitalization of 50.19 billion yuan [2]

证券代码：300289 证券简称：利德曼 公告编号：2025-026 北京利德曼生化股份有限公司 关于子公司重新签订房屋租赁合同暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 1、北京利德曼生化股份有限公司（以下简称"公司"）全资子公司广 州利德曼医疗科技有限公司（简称"广州利德曼"）于 2021 年 3 月 1 日与 广州开发区控股集团有限公司（简称"广开控股"）签订《房屋租赁合同》， 并与广州凯云智慧服务有限公司（简称"凯云服务"）签订了《物业管理 服务合同》，内容详见公司在巨潮资讯网（http://www.cninfo.com.cn）披 露的《关于全资子公司重新签订房屋租赁合同暨关联交易的公告》（公告 编号：2021-019）以及后续披露的《关于重新审议全资子公司房屋租赁 暨关联交易的公告》（公告编号：2024-007）。 2、根据所在园区最新的租赁政策，广州利德曼于近日与广开控股重 新签订《房屋租赁合同》，与广开控股委托的物业管理服务公司广州凯云 发展股份有限公司（简称"凯云发展"）签订《加速器园区管理服务合同》。 ...

Core Viewpoint - Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant net outflow of funds, indicating potential challenges in the market [1][2]. Company Overview - Lidman specializes in the research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1]. - The company's main products include biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1]. - Lidman has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and Innovative Enterprise" [1]. Financial Performance - For Q1 2025, Lidman reported revenue of 78.91 million yuan, a year-on-year decrease of 16.61% [1]. - The net profit for the same period was -1.25 million yuan, reflecting a year-on-year increase in losses of 53.73% [1]. - The gross profit margin stood at 53.56% [1]. Market Position - As of May 27, Lidman's stock closed at 4.98 yuan, with a market capitalization of 2.709 billion yuan and a price-to-book ratio of 1.63 [1]. - The company has seen a net outflow of 3.4978 million yuan in principal funds on May 27, with a total outflow of 7.7543 million yuan over the past five days [1]. Industry Comparison - Lidman's PE (TTM) ratio is -36.79, while the industry average is 49.11, indicating a significant disparity in valuation metrics [2]. - The industry median PE (TTM) is 35.89, suggesting that Lidman is underperforming compared to its peers [2].

Group 1 - The core viewpoint of the news is that Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant drop in stock performance and net outflow of funds [1] - As of May 20, Lidman’s stock closed at 5.04 yuan, up 1.61%, with a latest price-to-book ratio of 1.65, marking a 40-day low and a total market capitalization of 2.742 billion yuan [1] - In terms of fund flow, on May 20, Lidman saw a net outflow of 3.714 million yuan, with a total outflow of 7.288 million yuan over the past five days [1] Group 2 - The main business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company’s key products consist of biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1] - Recent performance data shows that in Q1 2025, Lidman achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25172554 million yuan, a year-on-year decline of 53.73%, with a gross profit margin of 53.56% [1] Group 3 - Lidman has received multiple accolades, including "National High-tech Enterprise," "Zhongguancun High-tech Enterprise," and recognition as a leading enterprise in the "G20 Project" for the Beijing biopharmaceutical industry [1] - The company was also recognized as a "Benchmark Enterprise in Intelligent Manufacturing" in Beijing for 2018 and received certification for "Digital Workshop" in 2022 [1]